Predictors of Progression-Free Survival and Local Tumor Control after Percutaneous Thermal Ablation of Oligometastatic Breast Cancer: Retrospective Study

To describe ablation of bone, liver, lung, and soft tissue tumors from oligometastatic breast cancer and to define predictors of local progression and progression-free survival (PFS). A total of 33 women (mean age 52 ± 12 years old; range, 28-69 years), underwent 46 thermal ablations of liver (n = 3...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Journal of vascular and interventional radiology Jg. 31; H. 8; S. 1201
Hauptverfasser: Ridouani, Fourat, Solomon, Stephen B, Bryce, Yolanda, Bromberg, Jacqueline F, Sofocleous, Constantinos T, Deipolyi, Amy R
Format: Journal Article
Sprache:Englisch
Veröffentlicht: United States 01.08.2020
Schlagworte:
Adult
Aged
Bone Neoplasms - diagnostic imaging
Bone Neoplasms - mortality
Bone Neoplasms - secondary
Bone Neoplasms - surgery
Breast Neoplasms - mortality
Breast Neoplasms - pathology
Cryosurgery - adverse effects
Cryosurgery - mortality
Databases, Factual
Disease Progression
Feasibility Studies
Female
Humans
Liver Neoplasms - diagnostic imaging
Liver Neoplasms - mortality
Liver Neoplasms - secondary
Liver Neoplasms - surgery
Lung Neoplasms - diagnostic imaging
Lung Neoplasms - mortality
Lung Neoplasms - secondary
Lung Neoplasms - surgery
Margins of Excision
Metastasectomy - adverse effects
Metastasectomy - methods
Metastasectomy - mortality
Middle Aged
Progression-Free Survival
Radiofrequency Ablation - adverse effects
Radiofrequency Ablation - mortality
Retrospective Studies
Risk Factors
Soft Tissue Neoplasms - diagnostic imaging
Soft Tissue Neoplasms - mortality
Soft Tissue Neoplasms - secondary
Soft Tissue Neoplasms - surgery
Time Factors
Tumor Burden
ISSN:1535-7732, 1535-7732
Online-Zugang:Weitere Angaben
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:To describe ablation of bone, liver, lung, and soft tissue tumors from oligometastatic breast cancer and to define predictors of local progression and progression-free survival (PFS). A total of 33 women (mean age 52 ± 12 years old; range, 28-69 years), underwent 46 thermal ablations of liver (n = 35), lung (n = 7), and bone/soft tissue (n = 4) metastases. Mean tumor diameter was 18 ± 15 mm (range, 6-50 mm). Ablations were performed to eradicate all evident sites of disease (n = 24) or to control growing sites in the setting of other stable or responding sites of disease (n = 22). Patient characteristics, ablation margins, imaging responses, and cases of PFS were assessed. Follow-up imaging was performed using contrast-enhanced computed tomography (CT), magnetic resonance (MR) imaging, or positron-emission tomography/ CT. Median PFS was 10 months (95% confidence interval [CI], 6.2 -14.5 months), and time to local progression was 11 months (95% CI, 5-16 months). Eight patients (24%) maintained no evidence of disease during a median follow-up period of 39 months. Ablation margin ≥5 mm was associated with no local tumor progression. Longer PFS was noted in estrogen receptor-positive patients (12 vs 4 months; P = .037) and younger patients (12 vs 4 months; P = .039) treated to eradicate all sites of disease (13 vs 5 months; P = .05). Eighteen patients (55%) developed new metastases during study follow-up. Thermal ablation of oligometastatic pulmonary, hepatic, bone, and soft tissue tumors can eliminate local tumor progression if margins are ≥5 mm. Longer PFS was observed in patients who were estrogen receptor-positive and patients who were younger and in whom all sites of disease were eradicated.
Bibliographie:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ISSN:1535-7732
1535-7732
DOI:10.1016/j.jvir.2020.02.016